Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Brasco One who wrote (1817)	3/9/1999 12:40:00 PM
From: marc ultra	Read Replies (1) \| Respond to of 2135

re<<<<<ENMD is only 20 years away from "maybe" earnings!>>>>>>> That sounds like a rather confident statement considering clinical trials of at least ES are occurring this year under NCI auspices and if there is indication of efficacy in initial trials it is likely to get accelerated through the process in record time let alone compassionate use which would become rampant. Furthermore indications are CELG's thalidomide is selling strong and ENMD gets a cut of this Yes the stuff can flop but if we hear one successful case report of compassionate use which could occur at any time, anyone who is short is unlikely to forget that day. Marc